CompletedPhase 1NCT04555486
Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients
Studying Primary hyperoxaluria type 3
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Principal Investigator
- Alexandra Haagensen, MD, MBA, MDDicerna Pharmaceuticals
- Intervention
- DCR-PHXC(drug)
- Enrollment
- 6 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2020 – 2021
Study locations (6)
- Clinical Trial Site, Boston, Massachusetts, United States
- Clinical Trial Site, Rochester, Minnesota, United States
- Clinical Trial Site, New York, New York, United States
- Clinical Trial Site, Bonn, Germany
- Clinical Trial Site, Amsterdam, Netherlands
- Clinical Trial Site, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04555486 on ClinicalTrials.gov